| Computational methods in drug discovery G Sliwoski, S Kothiwale, J Meiler, EW Lowe Jr, EL Barker Pharmacological reviews 66 (1), 334-395, 2014 | 2394 | 2014 |
| Psychedelics DE Nichols, EL Barker Pharmacological reviews 68 (2), 264-355, 2016 | 1923 | 2016 |
| Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery UB Pandey, CD Nichols, EL Barker Pharmacological reviews 63 (2), 411-436, 2011 | 1566 | 2011 |
| REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics RL Carhart-Harris, KJ Friston, EL Barker Pharmacological reviews 71 (3), 316-344, 2019 | 967 | 2019 |
| Endothelin AP Davenport, KA Hyndman, N Dhaun, C Southan, DE Kohan, JS Pollock, ... Pharmacological reviews 68 (2), 357-418, 2016 | 924 | 2016 |
| Current challenges and opportunities in treating glioblastoma A Shergalis, A Bankhead III, U Luesakul, N Muangsin, N Neamati, ... Pharmacological reviews 70 (3), 412-445, 2018 | 795 | 2018 |
| Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come P Yingchoncharoen, DS Kalinowski, DR Richardson, EL Barker Pharmacological reviews 68 (3), 701-787, 2016 | 792 | 2016 |
| Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options W Löscher, H Potschka, SM Sisodiya, A Vezzani, EL Barker Pharmacological reviews 72 (3), 606-638, 2020 | 708 | 2020 |
| Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia MR Hutchinson, Y Shavit, PM Grace, KC Rice, SF Maier, LR Watkins, ... Pharmacological reviews 63 (3), 772-810, 2011 | 457 | 2011 |
| Structure, function, and pharmacology of glutamate receptor ion channels KB Hansen, LP Wollmuth, D Bowie, H Furukawa, FS Menniti, ... Pharmacological reviews 73 (4), 1469-1658, 2021 | 436 | 2021 |
| Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery T Atkin, S Comai, G Gobbi, EL Barker Pharmacological reviews 70 (2), 197-245, 2018 | 394 | 2018 |
| Chemical probes of endocannabinoid metabolism JL Blankman, BF Cravatt, EL Barker Pharmacological reviews 65 (2), 849-871, 2013 | 366 | 2013 |
| The expanding roles of Gβγ subunits in G protein–coupled receptor signaling and drug action SM Khan, R Sleno, S Gora, P Zylbergold, JP Laverdure, JC Labbé, ... Pharmacological reviews 65 (2), 545-577, 2013 | 364 | 2013 |
| Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure LB Arendse, AHJ Danser, M Poglitsch, RM Touyz, JC Burnett Jr, ... Pharmacological reviews 71 (4), 539-570, 2019 | 358 | 2019 |
| Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. EL Barker, RS Westphal, D Schmidt, E Sanders-Bush Journal of Biological Chemistry 269 (16), 11687-11690, 1994 | 343 | 1994 |
| Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor JE Burdette, J Liu, S Chen, DS Fabricant, CE Piersen, EL Barker, ... Journal of agricultural and food chemistry 51 (19), 5661-5670, 2003 | 309 | 2003 |
| Rescuing the last-line polymyxins: achievements and challenges SC Nang, MAK Azad, T Velkov, QT Zhou, J Li, E Barker Pharmacological reviews 73 (2), 679-728, 2021 | 297 | 2021 |
| Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs EL Barker, RD Blakely Psychopharmacology: the fourth generation of progress 28, 321-333, 1995 | 290 | 1995 |
| Botanicals and their bioactive phytochemicals for women’s health BM Dietz, A Hajirahimkhan, TL Dunlap, JL Bolton, E Barker Pharmacological reviews 68 (4), 1026-1073, 2016 | 277 | 2016 |
| Biased receptor signaling in drug discovery T Kenakin, EL Barker Pharmacological reviews 71 (2), 267-315, 2019 | 248 | 2019 |
